Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial

P Lavaud , G Gravis , S Foulon , F Joly , S Oudard , F Priou , I Latorzeff , L Mourey , M Soulié (1) , R Delva , I Krakowski , B Laguerre , C Théodore , Jm Ferrero , P Beuzeboc , M Habibian , F Rolland , G Deplanque , D Pouessel , S Zanetta , Jf Berdah , J Dauba , M Baciuchka , C Platini , C Linassier , N Tubiana-Mathieu , Jp Machiels , Ce Kouri , A Ravaud , E Suc , Jc Eymard , A Hasbini , G Bousquet , S Culine , Jm Boher , G Tergemina-Clain , C Legoupil , K Fizazi

1 Département d'Urologie-Andrologie et Transplantation Rénale [CHU Toulouse]

Domaines: Sciences du Vivant [q-bio]

P Lavaud, G Gravis, S Foulon, F Joly, S Oudard, et al.. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. European Urology, 2017, ⟨10.1016/j.eururo.2017.09.022⟩. ⟨hal-01950269⟩